Buck research focuses on risk factor for Parkinson's disease

A new study demonstrates that high levels of MAO-B, an enzyme that regulates nerve activity in the brain, cause Parkinson’s-like symptoms in mice genetically engineered to overexpress the protein. Furthermore, drugs currently used as an adjunct therapy for Parkinson’s in humans prevented the development of Parkinson’s symptoms in these same animals. The findings, by scientists at the Buck Institute for Age Research, raise the possibility that humans could be tested to see if they have a risk factor for the progressive, incurable neurodegenerative disorder that affects 1.5 million Americans and receive preventive treatment. The study appears in the February 20 issue of the open-access, online journal, PLoS ONE.

Levels of measurable MAO-B vary 50-fold in humans and tend to increase with age. Several studies have suggested that increases in MAO-B contribute to the neurodegeneration associated with PD, but direct proof of a causative role for the enzyme has been lacking. The drug deprenyl, which inhibits MAO-B, is a longstanding therapy for Parkinson’s used together with drugs that boost the level of dopamine, an important neurotransmitter that is preferentially depleted in the disease. Clinical studies that suggest that deprenyl treatment alone does not impact mortality associated with Parkinson’s have cast doubt on the role of MAO-B in the disease itself.

Buck faculty member Julie Andersen, PhD, who led the study says that may not be the case. “Those studies were targeted to patients who already had symptoms of Parkinson’s -- by the time Parkinson’s is symptomatically detectable, dopamine loss is usually at least 60%,” said Andersen. “Therefore the lack of effectiveness of MAO-B inhibition in these patients does not negate a role for MAO-B increase in disease development.” Andersen added, “We have demonstrated that elevations in MAO-B result in selective loss of neurons associated with Parkinson’s in a mouse model and that the severity of this loss is age-dependent.”

Tests to measure levels of MAO-B are not currently available to the general public, although enzyme levels are tracked in clinical trials. Andersen says MAO-B testing could be akin to current practices involving cholesterol, which is measured and monitored as a risk factor for cardiovascular disease. “However, it is important to note that Parkinson’s is a multi-factor disease,” said Andersen. “The fact that someone has high levels of MAO-B does not necessarily mean they are fated to develop Parkinson’s.”

Andersen said results of the study point to the need for an early diagnostic test for Parkinson’s. "Currently, by the time people are diagnosed with the disease they have already lost 60% of the neurotransmitter levels implicated in Parkinson’s; treatment with a drug like deprenyl would likely be most effective if taken before symptoms appear in order to halt disease progression."

The novel transgenic mouse line created for this study provides a new model for exploring molecular pathways involved in the initiation or early progression of several key features associated with Parkinson’s pathology including dopaminergic midbrain cell loss. The mouse line also allows for additional therapeutic drug testing.

Source: Public Library of Science

Related stories:

Blood-related genetic mechanisms found important in Parkinson's disease
What does the genetics of blood cells have to do with brain cells related to Parkinson's disease? From an unusual collaboration of neurologists and a pharmacologist comes the surprising answer: Genetic mechanisms at play in blood cells also control a gene and protein that cause Parkinson's disease.
NVIDIA Announced New Geforce GTX 200 GPUs
Imagine instead of taking over five hours to convert a video for your iPod, it only takes 35 minutes. Imagine using your PC to simulate protein folding to help find a cure for debilitating diseases. Imagine that your PC can dramatically accelerate everyday tasks, and deliver an exciting visual experience in the process.
How to construct a 'firefly' worm
Research describing a new modified luminescent worm that allows, for the first time, to measure, in real time, the metabolism of an entire living organism has just been published in the journal BMC Physiology.
Mind over matter: Monkey feeds itself using its brain
A monkey has successfully fed itself with fluid, well-controlled movements of a human-like robotic arm by using only signals from its brain, researchers from the University of Pittsburgh School of Medicine report in the journal Nature. This significant advance could benefit development of prosthetics for people with spinal cord injuries and those with “locked-in” conditions such as Lou Gehrig’s disease, or amyotrophic lateral sclerosis.
Major 'missed' biochemical pathway emerges as important in virtually all cells
A new study by Duke University researchers provides more evidence that the nitric oxide (NO) system in the life of a cell plays a key role in disease, and the findings point to ways to improve treatment of illnesses such as heart disease and cancer.
Protein key to neuro-regeneration
Researchers at the Peninsula Medical School in the South West of England, University College London, the San Raffaele Scientific Institute in Milan and Cancer Research UK, have for the first time identified a protein that is key to the regeneration of damage in the peripheral nervous system and which could with further research lead to understanding diseases of our peripheral nervous systems and provide clues to methods of repairing damage in the central nervous system, according to a paper published this week in the Journal of Cell Biology.
Turning back the clock for Schwann cells
Myelin-making Schwann cells have an ability every aging Hollywood star would envy: they can become young again. According to a study appearing in the May 19 issue of the Journal of Cell Biology, David B. Parkinson (University College London, London, UK) and collogues have pinned down a protein that returns the cells to their youth, a finding that might help researchers understand why myelin production falters in some diseases.
Biosensor for measuring stress in cells
Cancer, nervous system disorders such as Parkinson’s disease, cardiovascular disorders and old age have one thing in common: Both in afflicted tissue and in aging cells, scientists have observed oxidative changes in important biomolecules. These are caused by reactive oxygen molecules, including the notorious “free radicals” that are formed as a by-product of cellular respiration and attack cellular proteins, nucleic and fatty acids.

News discussion:

Medicine & Health news